AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 1395977
Drug: Corticosteroid enemas
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid enemas (CS‐‐100 mg of hydrocortisone/60 cc P.R. q.h.s.; n = 12)
Trial: 1395977
Drug: Mesalamine enemas
RxNorm normalized name: mesalamine Enema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mesalamine enemas (5‐ASA‐‐4 g/60 cc P.R. q.h.s.; n = 19)
Trial: 1395977
Drug: Short-chain fatty
RxNorm normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short-chain fatty acid enemas (SCFA‐‐60 cc P.R. b.i.d.; n = 14)
Trial: 1395977
Drug: Cost of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cost of treatment for corticosteroid enemas
Trial: 1395977
Drug: Cost of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cost of treatment for mesalamine enemas
Trial: 1395977
Drug: Cost of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cost of treatment for short-chain fatty acid enemas
Trial: 2857601
Drug: Intravenous pinacidil,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous pinacidil, 0.2 mg/kg
Trial: 2857601
Drug: Hydralazine, 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydralazine, 0.3 mg/kg
Trial: 28956187
Drug: Schedule A:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Schedule A: every-3-week ixabepilone (32 mg/m2 on day 2) + vorinostat (300 mg daily, days 1-14)
Trial: 28956187
Drug: Schedule B:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Schedule B: weekly ixabepilone (16 mg/m2 on days 2, 9, 16) + vorinostat (300 mg daily, days 1-7; 15-21)
Trial: 25358221
Drug: Azithromycin 500
RxNorm normalized name: azithromycin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin 500 mg daily before meal for 4 consecutive days monthly for 3 months
Trial: 25358221
Drug: Doxycycline 100
RxNorm normalized name: doxycycline 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline 100 mg daily after meals for 3 months
Trial: 20182883
Drug: Subconjunctival injection
RxNorm normalized name: STREPTOMYCES GRISEUS 0.05 g in 1 mL SUBCONJUNCTIVAL INJECTION, SOLUTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subconjunctival injection of 0.5 ml dexamethasone diphosphate (10 mg)
Trial: 20182883
Drug: 0.5 ml
RxNorm normalized name: ethanol 0.5 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 ml placebo
Trial: 19087677
Drug: TXL capsule
RxNorm normalized name: TXL
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TXL capsule
Trial: 11338314
Drug: Drug treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug treatment for hypertension
Trial: 342623
Drug: Bivalent A/Victoria/75-A/New
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bivalent A/Victoria/75-A/New Jersey/76 influenza vaccine
Trial: 342623
Drug: Monovalent B/Hong
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monovalent B/Hong Kong/72 influenza vaccine
Trial: 342623
Drug: Bivalent A/Victoria/75-A/New
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bivalent A/Victoria/75-A/New Jersey/76 and Monovalent B/Hong Kong/72 influenza vaccines (given together)
Trial: 27589995
Drug: L-serine (0.5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-serine (0.5, 2.5, 7.5, or 15 g/dose, twice daily)
Trial: 15290417
Drug: Atenolol 25
RxNorm normalized name: atenolol 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol 25 mg oral premedication 1 hour before induction
Trial: 9360203
Drug: Cisapride (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisapride (0.2 mg/kg q6h)
Trial: 30892844
Drug: Dance therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dance therapy
Trial: 28012564
Drug: Methotrexate at
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate at a starting dose of 17.5 mg/week for the first 16 weeks, followed by methotrexate treatment up to 52 weeks.
Trial: 28012564
Drug: Placebo for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for the first 16 weeks, followed by methotrexate treatment up to 52 weeks.
Trial: 27481744
Drug: Hypocaloric enteral
RxNorm normalized name: Hydrochloric Acid
DrugBank: Hydrochloric acid (DB13366)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypocaloric enteral nutrition (15 kcal/kg per day) with hyperproteic intake (1.7 g of protein/kg per day)
Trial: 27481744
Drug: Normocaloric enteral
RxNorm normalized name: lipase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normocaloric enteral nutrition (25 kcal/kg per day) with hyperproteic intake (1.7 g of protein/kg per day)
Trial: 24816958
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin (BT) injection (20 U into internal anal sphincter)
Trial: 24816958
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin (BT) injection (20 U) and half-dose 0.2% glyceryltrinitrate (GTN) cream (thrice daily for 6 weeks)
Trial: 24816958
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin (BT) injection (20 U)
Trial: 24816958
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin (BT) injection (20 U) and half-dose 0.2% glyceryltrinitrate (GTN) cream
Trial: 22879656
Drug: DEX 0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DEX 0.15 mg kg(‐1)
Trial: 22879656
Drug: DEX 0.5
RxNorm normalized name: Stri-Dex 0.5 % Medicated Pad
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DEX 0.5 mg kg(‐1)
Trial: 19662630
Drug: Antidepressant (ADT)
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant (ADT) monotherapy
Trial: 17565929
Drug: Fixed combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed combination latanoprost/timolol
Trial: 9638417
Drug: Verapamil 80
RxNorm normalized name: verapamil 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil 80 mg peroral
Trial: 2554500
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin fraction CY 216
Trial: 28590828
Drug: Sildenafil 25
RxNorm normalized name: sildenafil 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil 25 mg qd
Trial: 28590828
Drug: Sildenafil 25
RxNorm normalized name: sildenafil 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil 25 mg bid
Trial: 28590828
Drug: Sildenafil 50
RxNorm normalized name: sildenafil 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil 50 mg qd
Trial: 25425015
Drug: Felodipine sustained-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Felodipine sustained-release tablets
Trial: 20031845
Drug: Multilevel, multicomponent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multilevel, multicomponent intervention (interactive computerized hypertension education, home BP monitoring, monthly behavioral counseling)
Trial: 16678643
Drug: Acetaminophen 4
RxNorm normalized name: acetaminophen 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen 4 g/d for up to 12 months
Trial: 16678643
Drug: Naproxen 750
RxNorm normalized name: naproxen 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen 750 mg/d for up to 12 months
Trial: 16678643
Drug: Naproxen 750
RxNorm normalized name: naproxen 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen 750 mg/d
Trial: 9412611
Drug: Lubeluzole (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lubeluzole (7.5 mg over 1 hour, followed by a continuous daily infusion of 10 mg for up to 5 days)
Trial: 2894247
Drug: Isoproterenol injections
RxNorm normalized name: isoproterenol Injection
DrugBank: Isoprenaline (DB01064)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isoproterenol injections
Trial: 2894247
Drug: Cream containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cream containing colforsin (forskolin), aminophylline, and yohimbine
Trial: 2894247
Drug: Yohimbine cream
RxNorm normalized name: YOHIMBINE
DrugBank: Yohimbine (DB01392)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yohimbine cream
Trial: 2894247
Drug: Colforsin cream
RxNorm normalized name: Colforsin
DrugBank: Colforsin (DB02587)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colforsin cream
Trial: 2894247
Drug: Aminophylline cream
RxNorm normalized name: Aminophylline
DrugBank: Aminophylline (DB01223)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aminophylline cream
Trial: 2894247
Drug: Placebo (injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (injection or cream)
Trial: 22841478
Drug: 5 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 μg of virus protein per 0.5 mL formulation
Trial: 22841478
Drug: 2.5 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 μg of virus protein per 0.5 mL formulation
Trial: 22841478
Drug: 1.25 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.25 μg of virus protein per 0.5 mL formulation
Trial: 18688013
Drug: 15 mg/h
RxNorm normalized name: buprenorphine 0.015 MG/HR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg/h clazosentan
Trial: 18688013
Drug: 1 mg/h
RxNorm normalized name: fentanyl 0.1 MG/HR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/h clazosentan
Trial: 28463833
Drug: 5 mg/h
RxNorm normalized name: fentanyl 0.05 MG/HR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/h clazosentan
Trial: 16187967
Drug: Sustained release
RxNorm normalized name: Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained release isosorbide 5' mono-nitrate (ISMN) 120 mg
Trial: 16187967
Drug: Transdermal nitroglycerine
RxNorm normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal nitroglycerine (TD-NTG) 15 mg 24 h(‐1)
Trial: 16187967
Drug: Sodium nitroprusside
RxNorm normalized name: Sodium Nitroprusside
DrugBank: Nitroprusside (DB00325)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Sodium nitroprusside (SNP) 10 micromol l(‐1)
Trial: 16187967
Drug: Nitroglycerine (NTG)
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerine (NTG) 100 micromol l(‐1)
Trial: 16187967
Drug: ADP (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADP (1 micromol l(‐1))
Trial: 1993133
Drug: Intravenous streptokinase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous streptokinase 1.5 x 10(6) IU (n = 55)
Trial: 1993133
Drug: Placebo infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo infusion (n = 26)
Trial: 25487798
Drug: GSK1322322 (oral-i.v.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK1322322 (oral-i.v. combination)
Trial: 24052491
Drug: High-dose, short-duration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose, short-duration dietary oral supplementation of n-3 polyunsaturated fatty acids (n-3 PUFA)
Trial: 11812666
Drug: Digitalis administration
RxNorm normalized name: Digitalis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digitalis administration in supine position
Trial: 11812666
Drug: Digitalis administration
RxNorm normalized name: Digitalis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digitalis administration in supine position with leg elevation
Trial: 11812666
Drug: Digitalis administration
RxNorm normalized name: Digitalis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digitalis administration in LVD patients
Trial: 10409470
Drug: Pamidronate 60
RxNorm normalized name: pamidronate 60 mg intravenous powder for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pamidronate 60 mg intravenously pre-operatively
Trial: 2147517
Drug: amitriptyline (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: amitriptyline (150 mg/day)
Trial: 16172700
Drug: Fluoxetine (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (0.25 to 0.50 mg/kg for three months)
Trial: 12441944
Drug: Noncontact laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Noncontact laser therapy
Trial: 16086927
Drug: Enalapril (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (10 mg twice a day)
Trial: 10096264
Drug: Enalapril (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (standard treatment for high blood pressure)
Trial: 7577202
Drug: Daunorubicin and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daunorubicin and cytarabine with granulocyte colony-stimulating factor (G-CSF) as supportive care
Trial: 7577202
Drug: Daunorubicin and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daunorubicin and cytarabine without granulocyte colony-stimulating factor (G-CSF)
Trial: 2013680
Drug: Immunotherapy (IT)
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy (IT) with a maintenance dose of 1.94 micrograms of antigen E (Amb a I) for 8 months (total dose equivalent to 24 micrograms of antigen E)
Trial: 6756509
Drug: Chemotherapy +
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy + Tamoxifen + Immunotherapy
Trial: 6756509
Drug: BCG Immunotherapy
RxNorm normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCG Immunotherapy
Trial: 30563829
Drug: Rapamycin (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapamycin (3 mg orally daily)
Trial: 29218705
Drug: Rapid AED
RxNorm normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapid AED taper (30% to 50% dose reduction)
Trial: 29218705
Drug: Slow AED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow AED taper (15% to <30% dose reduction)
Trial: 29218705
Drug: Rapid AED
RxNorm normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapid AED taper
Trial: 29218705
Drug: Slow AED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow AED taper
Trial: 24754230
Drug: Biological attributions
RxNorm normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biological attributions
Trial: 21997197
Drug: Intravitreal bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravitreal bevacizumab (IVB) - 2 injections of 1.25 mg with 6-week intervals
Trial: 21997197
Drug: Intravitreal bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravitreal bevacizumab combined with triamcinolone (IVB/IVT) - 1.25 mg of IVB with 2 mg of IVT
Trial: 21997197
Drug: Intravitreal triamcinolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal triamcinolone (IVT) - 2 mg of IVT
Trial: 17665231
Drug: Amphotericin B
RxNorm normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amphotericin B (monotherapy)
Trial: 17665231
Drug: Fluconazole (monotherapy)
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluconazole (monotherapy)
Trial: 17665231
Drug: Flucytosine (monotherapy)
RxNorm normalized name: Flucytosine
DrugBank: Flucytosine (DB01099)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flucytosine (monotherapy)
Trial: 17665231
Drug: Itraconazole (monotherapy)
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Itraconazole (monotherapy)
Trial: 20139214
Drug: Immediate antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate antibiotics
Trial: 20139214
Drug: Delayed antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed antibiotics
Trial: 10463975
Drug: Hepatic arterial
RxNorm normalized name: Sus scrofa artery preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatic arterial chemoembolization combined with systemic infusion of 5-fluorouracil and bolus leucovorin
Trial: 2113036
Drug: Balanced amino
RxNorm normalized name: silk amino acids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balanced amino acid solution (Study group)
Trial: 28421677
Drug: MBSR (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MBSR (8 weekly group sessions of MBSR)
Trial: 25944411
Drug: Zoledronate (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zoledronate (5 mg administered intravenously) plus diet counselling
Trial: 25944411
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of zoledronate (5 mg administered intravenously) plus diet counselling
Trial: 25944411
Drug: Two doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two doses of zoledronate (5 mg administered intravenously) plus diet counselling
Trial: 16484504
Drug: High trough
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High trough concentration (10‐15 ng/ml) group (HT group)
Trial: 8633831
Drug: Once-daily aminoglycoside
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily aminoglycoside dosing
Trial: 1421050
Drug: Tegretol 200
RxNorm normalized name: Tegretol 200mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tegretol 200 mg commercial tablets
Trial: 1421050
Drug: carbamazepine OROS
RxNorm normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: carbamazepine OROS controlled delivery tablets
Trial: 27510380
Drug: DTaP‐IPV//Hib pentavalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTaP‐IPV//Hib pentavalent combination vaccine (Pentaxim™)
Trial: 27510380
Drug: Separate DTaP‐IPV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Separate DTaP‐IPV and Hib vaccines
Trial: 25061038
Drug: Placebo SWD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo SWD treatment
Trial: 19451282
Drug: EDP-420 (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EDP-420 (400 mg/day loading dose, followed by 200 mg/day for 2 days)
Trial: 19451282
Drug: EDP-420 capsule
RxNorm normalized name: INDIGOFERA TINCTORIA LEAF 0.999 in 100 g TOPICAL POWDER [EDP INDIGO]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EDP-420 capsule formulation
Trial: 19451282
Drug: EDP-420 suspension
RxNorm normalized name: INDIGOFERA TINCTORIA LEAF 0.999 in 100 g TOPICAL POWDER [EDP INDIGO]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EDP-420 suspension formulation
Trial: 16505262
Drug: Cholecalciferol (700
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholecalciferol (700 IU) plus Calcium Citrate Malate (500 mg)
Trial: 8000747
Drug: Verum acupuncture
RxNorm normalized name: Cinnamomum verum whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verum acupuncture treatment at non-segmental distal points (homolateral leg)
Trial: 3287976
Drug: Cefotetan 2
RxNorm normalized name: cefotetan 2000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefotetan 2 g once daily
Trial: 3287976
Drug: Cefoxitin 1
RxNorm normalized name: cefoxitin 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefoxitin 1 or 2 g three times daily
Trial: 3927481
Drug: Bezafibrate 200
RxNorm normalized name: bezafibrate 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bezafibrate 200 mg 3 times daily
Trial: 22915294
Drug: Cowpea meal
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cowpea meal fortified with 10 mg Fe/meal as NaFeEDTA
Trial: 19115654
Drug: Lignocaine alone
RxNorm normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lignocaine alone (9 ml of 2% lignocaine diluted with normal saline to total volume of 36 ml)
Trial: 19115654
Drug: Lignocaine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lignocaine plus magnesium sulphate (6 ml of 25% magnesium sulphate plus 9 ml of 2% lignocaine diluted with normal saline to total volume of 36 ml)
Trial: 3943744
Drug: Hyoscine‐N‐butylbromide (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyoscine‐N‐butylbromide (20 mg IV)
Trial: 3943744
Drug: Hyoscine‐N‐butylbromide (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyoscine‐N‐butylbromide (40 mg IV)
Trial: 24767296
Drug: Short-term thromboprophylaxis
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term thromboprophylaxis with oral rivaroxaban 10 mg once daily for 7 days
Trial: 24767296
Drug: Long-term thromboprophylaxis
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term thromboprophylaxis with oral rivaroxaban 10 mg once daily for 35 days
Trial: 23248894
Drug: Novel multi-directional
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novel multi-directional power toothbrush (Oral-B Professional Deep Sweep TRICLEAN 1000)
Trial: 11978683
Drug: NVP DPP728
RxNorm normalized name: NVP
DrugBank: Nevirapine (DB00238)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NVP DPP728 at 100 mg t.i.d.
Trial: 11978683
Drug: NVP DPP728
RxNorm normalized name: NVP
DrugBank: Nevirapine (DB00238)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NVP DPP728 at 150 mg b.i.d.
Trial: 11978683
Drug: NVP DPP728
RxNorm normalized name: NVP
DrugBank: Nevirapine (DB00238)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NVP DPP728 (combined active treatment groups)